SIR-Spheres Microspheres (Sirtex) benefit both elderly and younger patients with Liver Cancer
An analysis of a study of SIR-Spheres microspheres, from Sirtex, in the treatment of patients with inoperable primary Liver Cancer, found essentially identical long-term treatment outcomes following radioembolisation using SIR-Spheres in 128 elderly (age 70 years or older) compared to 197 younger (less than 70 years of age) patients with otherwise similar demographics. Overall survival of patients in the study was not statistically significant between elderly (median 14.5 months) and younger (12.8 months) patients. There was also no significant difference in survival between very elderly patients (75 years or older) and those under that age (median 14.9 vs. 12.8 months).
Radioembolisation with SIR-Spheres was equally well-tolerated in both age groups. Severe GI ulcers (grade 3 and above) were actually almost three times less common among older patients (0.8% vs. 2.7%). Data were published in the Journal of Hepatology. See: "Comparison of the survival and tolerability of radioembolization in elderly versus younger patients with unresectable hepatocellular carcinoma." Golfieri R et al. Journal of Hepatology 2013; doi: dx.doi.org/10.1016/j.jhep.2013.05.025
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).